Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1.

Rodriguez-Gutierrez R, Gionfriddo MR, Ospina NS et al (2016) Shared decision making in endocrinology: present and future directions. Lancet Diabetes Endocrinol 4(8):706–716. https://doi.org/10.1016/S2213-8587(15)00468-4CrossRefPubMed

2.

American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G et al (2022) 6. Glycemic targets: standards of medical care in diabetes – 2022. Diabetes Care 45(Suppl 1):S83–S96. https://doi.org/10.2337/dc22-S006

3.

Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centred approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55(6):1577–1596. https://doi.org/10.1007/s00125-012-2534-0CrossRefPubMed

4.

Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58(3):429–442. https://doi.org/10.1007/s00125-014-3460-0CrossRefPubMed

5.

Davies M, D’Alessio DA, Fradkin J et al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 61(12):2461–2498. https://doi.org/10.1007/s00125-018-4729-5CrossRefPubMed

6.

Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 Update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63(2):221–228. https://doi.org/10.1007/s00125-019-05039-wCrossRefPubMed

7.

Schandelmaier S, Briel M, Varadhan R et al (2020) Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 192(32):E901–E906. https://doi.org/10.1503/cmaj.200077

8.

Sun X, Ioannidis JPA, Agoritsas T, Alba AC, Guyatt G (2014) How to use a subgroup analysis: users’ guide to the medical literature. JAMA 311(4):405–411. https://doi.org/10.1001/jama.2013.285063CrossRefPubMed

9.

Andrews J, Guyatt G, Oxman AD et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66(7):719–725. https://doi.org/10.1016/j.jclinepi.2012.03.013CrossRefPubMed

10.

Santesso N, Glenton C, Dahm P et al (2020) GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 119:126–135. https://doi.org/10.1016/j.jclinepi.2019.10.014CrossRefPubMed

11.

Sun S, Hisland L, Grenet G et al (2021) Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type 2 diabetes: a meta-analysis of randomised control-trials. Therapie 77(4):413–423. https://doi.org/10.1016/j.therap.2021.10.002

12.

Agrawal L, Azad N, Bahn GD et al (2018) Long-term follow-up of intensive glycaemic control on renal outcomes in the Veterans Affairs Diabetes Trial (VADT). Diabetologia 61(2):295–299. https://doi.org/10.1007/s00125-017-4473-2CrossRefPubMed

13.

Lind M, Imberg H, Coleman RL, Nerman O, Holman RR (2021) Historical HbA_1c values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care 44(10):2231–2237. https://doi.org/10.2337/dc20-2439CrossRefPubMedCentral

14.

Riddle MC, Gerstein HC, Holman RR et al (2018) A1C targets should be personalized to maximize benefits while limiting risks. Diabetes Care 41(6):1121–1124. https://doi.org/10.2337/dci18-0018CrossRefPubMed

15.

Sargeant JA, Brady EM, Zaccardi F et al (2020) Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials. Diabetologia 63(8):1516–1520. https://doi.org/10.1007/s00125-020-05174-9CrossRefPubMedPubMedCentral

16.

American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G et al (2022) 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S125–S143. https://doi.org/10.2337/dc22-S009

17.

Crabtree T, Ogendo JJ, Vinogradova Y, Gordon J, Idris I (2022) Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. Expert Rev Endocrinol Metab 17(3):255–267. https://doi.org/10.1080/17446651.2022.2079495CrossRefPubMed

18.

Dickinson JK, Guzman SJ, Maryniuk MD et al (2017) The use of language in diabetes care and education. Diabetes Care 40(12):1790–1799. https://doi.org/10.2337/dci17-0041CrossRefPubMed

19.

Powers MA, Bardsley JK, Cypress M et al (2020) Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care and Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care 43(7):1636–1649. https://doi.org/10.2337/dci20-0023CrossRefPubMed

20.

Davis J, Fischl AH, Beck J et al (2022) 2022 National standards for diabetes self-management education and support. Diabetes Care 45(2):484–494. https://doi.org/10.2337/dc21-2396CrossRefPubMed

21.

National Institute for Health and Care Excellence (NICE) (2022) Type 2 diabetes in adults: management. Recommendations. NICE guideline [NG28]. Available from www.nice.org.uk/guidance/ng28/chapter/Recommendations#patient-education. Accessed 4 Jun 2022

22.

American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G et al (2022) 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S60–S82. https://doi.org/10.2337/dc22-S005

23.

Department of Health and Diabetes UK (2005) Structured patient education in diabetes: report from the Patient Education Working Group. Available from www.diabetes.org.uk/resources-s3/2017-11/structuredpatiented.pdf. Accessed 5 Aug 2022

24.

National Institute for Health and Clinical Excellence (NICE) (2016) Diabetes in adults. Quality statements 2 and 3. Quality standard [QS6]. Available from www.nice.org.uk/guidance/qs6. Accessed 18 Aug 2022

25.

Chrvala CA, Sherr D, Lipman RD (2016) Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. Patient Educ Couns 99(6):926–943. https://doi.org/10.1016/j.pec.2015.11.003CrossRefPubMed

26.

Pillay J, Armstrong MJ, Butalia S et al (2015) Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med 163(11):848–860. https://doi.org/10.7326/M15-1400CrossRefPubMed

27.

Zhao FF, Suhonen R, Koskinen S, Leino-Kilpi H (2017) Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Adv Nurs 73(4):812–833. https://doi.org/10.1111/jan.13163CrossRefPubMed

28.

Odgers-Jewell K, Ball LE, Kelly JT, Isenring EA, Reidlinger DP, Thomas R (2017) Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression. Diabet Med 34(8):1027–1039. https://doi.org/10.1111/dme.13340CrossRefPubMed

29.

He X, Li J, Wang B et al (2017) Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. Endocrine 55(3):712–731. https://doi.org/10.1007/s12020-016-1168-2CrossRefPubMed

30.

Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K (2018) Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol 6(2):130–142. https://doi.org/10.1016/S2213-8587(17)30239-5CrossRefPubMed

31.

Captieux M, Pearce G, Parke HL et al (2018) Supported self-management for people with type 2 diabetes: a meta-review of quantitative systematic reviews. BMJ Open 8(12):e024262. https://doi.org/10.1136/bmjopen-2018-024262CrossRefPubMedPubMedCentral

32.

Lindekilde N, Scheuer SH, Rutters F et al (2022) Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. Diabetologia 65(3):440–456. https://doi.org/10.1007/s00125-021-05609-xCrossRefPubMed

33.

Dening J, Islam SMS, George E, Maddison R (2020) Web-based interventions for dietary behavior in adults with type 2 diabetes: systematic review of randomized controlled trials. J Med Internet Res 22(8):e16437. https://doi.org/10.2196/16437CrossRefPubMedPubMedCentral

34.

Nkhoma DE, Jenya Soko C, Joseph Banda K, Greenfield D, Li YCJ, Iqbal U (2021) Impact of DSMES app interventions on medication adherence in type 2 diabetes mellitus: systematic review and meta-analysis. BMJ Health Care Inform 28(1):e100291. https://doi.org/10.1136/bmjhci-2020-100291CrossRef

35.

Omar MA, Hasan S, Palaian S, Mahameed S (2020) The impact of a self-management educational program coordinated through WhatsApp on diabetes control. Pharm Pract 18(2):1841. https://doi.org/10.18549/PharmPract.2020.2.1841CrossRef

36.

Quinn LM, Davies MJ, Northern A et al (2021) Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic. Diabet Med 38(3):e14469. https://doi.org/10.1111/dme.14469

37.

Gershkowitz BD, Hillert CJ, Crotty BH (2021) Digital coaching strategies to facilitate behavioral change in type 2 diabetes: a systematic review. J Clin Endocrinol Metab 106(4):e1513–e1520. https://doi.org/10.1210/clinem/dgaa850CrossRefPubMed

38.

Lee MK, Lee DY, Ahn HY, Park CY (2021) A novel user utility score for diabetes management using tailored mobile coaching: secondary analysis of a randomized controlled trial. JMIR MHealth UHealth 9(2):e17573. https://doi.org/10.2196/17573CrossRefPubMedPubMedCentral

39.

Ahlqvist E, Storm P, Käräjämäki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6(5):361–369. https://doi.org/10.1016/S2213-8587(18)30051-2CrossRefPubMed

40.

Pigeyre M, Hess S, Gomez MF et al (2022) Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. Diabetologia 65(1):206–215. https://doi.org/10.1007/s00125-021-05567-4CrossRefPubMed

41.

American Diabetes Association Professional Practice Committee (2022) 1. Improving care and promoting health in populations: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S8–16. https://doi.org/10.2337/dc22-S001CrossRef

42.

Kunneman M, Montori VM, Castaneda-Guarderas A, Hess EP (2016) What is shared decision making? (and what it is not). Acad Emerg Med 23(12):1320–1324. https://doi.org/10.1111/acem.13065

43.

Breslin M, Mullan RJ, Montori VM (2008) The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns 73(3):465–472. https://doi.org/10.1016/j.pec.2008.07.024CrossRefPubMed

44.

Mullan RJ, Montori VM, Shah ND et al (2009) The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 169(17):1560–1568. https://doi.org/10.1001/archinternmed.2009.293CrossRefPubMed

45.

Stacey D, Légaré F, Lewis K et al (2017) Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 4:CD001431. https://doi.org/10.1111/cpr.13301CrossRefPubMed

46.

Haire-Joshu D, Hill-Briggs F (2019) The next generation of diabetes translation: a path to health equity. Annu Rev Public Health 40:391–410. https://doi.org/10.1146/annurev-publhealth-040218-044158CrossRefPubMed

47.

Hill-Briggs F, Adler NE, Berkowitz SA et al (2021) Social determinants of health and diabetes: a scientific review. Diabetes Care 44(1):258–279. https://doi.org/10.2337/dci20-0053CrossRef

48.

Hill-Briggs F, Ephraim PL, Vrany EA et al (2022) Social determinants of health, race, and diabetes population health improvement: Black/African Americans as a population exemplar. Curr Diab Rep 22(3):117–128. https://doi.org/10.1007/s11892-022-01454-3CrossRefPubMedPubMedCentral

49.

Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M (2016) Psychosocial care for people with diabetes: a Position Statement of the American Diabetes Association. Diabetes Care 39(12):2126–2140. https://doi.org/10.2337/dc16-2053CrossRefPubMedPubMedCentral

50.

Lingvay I, Sumithran P, Cohen RV, le Roux CW (2022) Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet 399(10322):394–405. https://doi.org/10.1016/S0140-6736(21)01919-X

51.

Riddle MC, Cefalu WT, Evans PH et al (2021) Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 44(10):2438–2444. https://doi.org/10.2337/dci21-0034CrossRefPubMedCentral

52.

American Diabetes Association Professional Practice Committee (2022) 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S17–S38. https://doi.org/10.2337/dc22-S002CrossRef

53.

American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G et al (2022) 7. Diabetes technology: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S97–S112. https://doi.org/10.2337/dc22-S007CrossRef

54.

Mannucci E, Antenore A, Giorgino F, Scavini M (2018) Effects of structured versus unstructured self-monitoring of blood glucose on glucose control in patients with non-insulin-treated type 2 diabetes: a meta-analysis of randomized controlled trials. J Diabetes Sci Technol 12(1):183–189. https://doi.org/10.1177/1932296817719290CrossRefPubMed

55.

Young LA, Buse JB, Weaver MA et al (2017) Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial. JAMA Intern Med 177(7):920–929. https://doi.org/10.1001/jamainternmed.2017.1233CrossRefPubMedPubMedCentral

56.

National Institute for Health and Care Excellence (NICE) Type 2 diabetes in adults: management. Overview. NICE guideline [NG28]. Available from www.nice.org.uk/guidance/ng28. Accessed 28 Jul 2022

57.

Lu J, Ma X, Zhou J et al (2018) Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care 41(11):2370–2376. https://doi.org/10.2337/dc18-1131CrossRefPubMed

58.

Egede LE, Gebregziabher M, Echols C, Lynch CP (2014) Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother 48(5):562–570. https://doi.org/10.1177/1060028014526362CrossRefPubMed

59.

Huber CA, Reich O (2016) Medication adherence in patients with diabetes mellitus: does physician drug dispensing enhance quality of care? Evidence from a large health claims database in Switzerland. Patient Prefer Adherence 10:1803–1809. https://doi.org/10.2147/PPA.S115425CrossRefPubMedPubMedCentral

60.

Iglay K, Cartier SE, Rosen VM et al (2015) Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin 31(7):1283–1296. https://doi.org/10.1185/03007995.2015.1053048CrossRefPubMed

61.

McGovern A, Tippu Z, Hinton W, Munro N, Whyte M, de Lusignan S (2018) Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 20(4):1040–1043. https://doi.org/10.1111/dom.13160CrossRefPubMed

62.

Khunti K, Seidu S, Kunutsor S, Davies M (2017) Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care 40(11):1588–1596. https://doi.org/10.2337/dc16-1925CrossRefPubMed

63.

Polonsky WH, Henry RR (2016) Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence 10:1299–1307. https://doi.org/10.2147/PPA.S106821

64.

Konstantinou P, Kassianos AP, Georgiou G et al (2020) Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with recommendations for intervention development. Transl Behav Med 10(6):1390–1398. https://doi.org/10.1093/tbm/ibaa118CrossRefPubMed

65.

Lasalvia P, Barahona-Correa JE, Romero-Alvernia DM et al (2016) Pen devices for insulin self-administration compared with needle and vial: systematic review of the literature and meta-analysis. J Diabetes Sci Technol 10(4):959–966. https://doi.org/10.1177/1932296816633721CrossRefPubMedPubMedCentral

66.

Khunti K, Davies MJ (2017) Clinical inertia—time to reappraise the terminology? Prim Care Diabetes 11(2):105–106. https://doi.org/10.1016/j.pcd.2017.01.007CrossRefPubMed

67.

Furler J, O’Neal D, Speight J et al (2017) Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. BMJ. https://doi.org/10.1136/bmj.j783

68.

Manski-Nankervis JA, Furler J, O’Neal D, Ginnivan L, Thuraisingam S, Blackberry I (2017) Overcoming clinical inertia in insulin initiation in primary care for patients with type 2 diabetes: 24-month follow-up of the Stepping Up cluster randomised controlled trial. Prim Care Diabetes 11(5):474–481. https://doi.org/10.1016/j.pcd.2017.06.005CrossRefPubMed

69.

Tabesh M, Magliano DJ, Koye DN, Shaw JE (2018) The effect of nurse prescribers on glycaemic control in type 2 diabetes: a systematic review and meta -analysis. Int J Nurs Stud 78:37–43. https://doi.org/10.1016/j.ijnurstu.2017.08.018CrossRefPubMed

70.

Murphy ME, Byrne M, Galvin R, Boland F, Fahey T, Smith SM (2017) Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of healthcare interventions in primary care and community settings. BMJ Open 7(8):e015135. https://doi.org/10.1136/bmjopen-2016-015135CrossRefPubMedPubMedCentral

71.

American Diabetes Association (2022) Introduction: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S1–S2. https://doi.org/10.2337/dc22-SintCrossRef

72.

Sainsbury E, Kizirian NV, Partridge SR, Gill T, Colagiuri S, Gibson AA (2018) Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 139:239–252. https://doi.org/10.1016/j.diabres.2018.02.026CrossRefPubMed

73.

Snorgaard O, Poulsen GM, Andersen HK, Astrup A (2017) Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care 5(1):e000354. https://doi.org/10.1136/bmjdrc-2016-000354CrossRefPubMedPubMedCentral

74.

van Zuuren EJ, Fedorowicz Z, Kuijpers T, Pijl H (2018) Effects of low-carbohydrate- compared with low-fat-diet interventions on metabolic control in people with type 2 diabetes: a systematic review including GRADE assessments. Am J Clin Nutr 108(2):300–331. https://doi.org/10.1093/ajcn/nqy096CrossRefPubMed

75.

Schwingshackl L, Chaimani A, Hoffmann G, Schwedhelm C, Boeing H (2018) A network meta-analysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol 33(2):157–170. https://doi.org/10.1007/s10654-017-0352-xCrossRefPubMedPubMedCentral

76.

Martínez-González MA, Gea A, Ruiz-Canela M (2019) The Mediterranean diet and cardiovascular health. Circ Res 124(5):779–798. https://doi.org/10.1161/CIRCRESAHA.118.313348CrossRefPubMed

77.

Estruch R, Ros E, Salas-Salvadó J et al (2018) Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med 378(25):e34. https://doi.org/10.1056/NEJMoa1800389CrossRefPubMed

78.

Papamichou D, Panagiotakos DB, Itsiopoulos C (2019) Dietary patterns and management of type 2 diabetes: a systematic review of randomised clinical trials. Nutr Metab Cardiovasc Dis NMCD 29(6):531–543. https://doi.org/10.1016/j.numecd.2019.02.004CrossRefPubMed

79.

Wang X, Li Q, Liu Y, Jiang H, Chen W (2021) Intermittent fasting versus continuous energy-restricted diet for patients with type 2 diabetes mellitus and metabolic syndrome for glycemic control: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 179:109003. https://doi.org/10.1016/j.diabres.2021.109003CrossRefPubMed

80.

Carter S, Clifton PM, Keogh JB (2018) Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. JAMA Netw Open 1(3):e180756. https://doi.org/10.1001/jamanetworkopen.2018.0756CrossRefPubMedPubMedCentral

81.

Carter S, Clifton PM, Keogh JB (2019) The effect of intermittent compared with continuous energy restriction on glycaemic control in patients with type 2 diabetes: 24-month follow-up of a randomised noninferiority trial. Diabetes Res Clin Pract 151:11–19. https://doi.org/10.1016/j.diabres.2019.03.022CrossRefPubMed

82.

Corley BT, Carroll RW, Hall RM, Weatherall M, Parry-Strong A, Krebs JD (2018) Intermittent fasting in type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med 35(5):588–594. https://doi.org/10.1111/dme.13595

83.

O’Neil PM, Miller-Kovach K, Tuerk PW et al (2016) Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. Obesity (Silver Spring) 24(11):2269–2277. https://doi.org/10.1002/oby.21616

84.

Mottalib A, Salsberg V, Mohd-Yusof BN et al (2018) Effects of nutrition therapy on HbA_1c and cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. Nutr J 17(1):42. https://doi.org/10.1186/s12937-018-0351-0CrossRefPubMedPubMedCentral

85.

Chee WSS, Gilcharan Singh HK, Hamdy O et al (2017) Structured lifestyle intervention based on a trans-cultural diabetes-specific nutrition algorithm (tDNA) in individuals with type 2 diabetes: a randomized controlled trial. BMJ Open Diabetes Res Care 5(1):e000384. https://doi.org/10.1136/bmjdrc-2016-000384CrossRefPubMedPubMedCentral

86.

Mohd Yusof BN, Hasbullah FY, Mohd Shahar AS et al (2021) Changes in dietary intake improve glycemic control following a structured nutrition therapy during Ramadan in individuals with type 2 diabetes. Clin Nutr ESPEN 46:314–324. https://doi.org/10.1016/j.clnesp.2021.09.738CrossRefPubMed

87.

Mohd Yusof BN, Wan Zukiman WZHH, Abu Zaid Z et al (2020) Comparison of structured nutrition therapy for Ramadan with standard care in type 2 diabetes patients. Nutrients 12(3):E813. https://doi.org/10.3390/nu12030813CrossRefPubMed

88.

Lean ME, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 391(10120):541–551. https://doi.org/10.1016/S0140-6736(17)33102-1CrossRefPubMed

89.

Lean MEJ, Leslie WS, Barnes AC et al (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol 7(5):344–355. https://doi.org/10.1016/S2213-8587(19)30068-3CrossRefPubMed

90.

Wing RR, Look AHEAD Research Group (2021) Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? Findings from the Look AHEAD randomized trial. Obesity (Silver Spring) 29(8):1246–1258. https://doi.org/10.1002/oby.23158

91.

Houston DK, Neiberg RH, Miller ME et al (2018) Physical function following a long-term lifestyle intervention among middle aged and older adults with type 2 diabetes: the Look AHEAD study. J Gerontol A Biol Sci Med Sci 73(11):1552–1559. https://doi.org/10.1093/gerona/glx204CrossRefPubMed

92.

Garvey WT (2021) Long-term health benefits of intensive lifestyle intervention in the Look AHEAD study. Obesity (Silver Spring) 29(8):1242–1243. https://doi.org/10.1002/oby.23198

93.

Look AHEAD Research Group; Wing RR, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369(2):145–154. https://doi.org/10.1056/NEJMoa1212914

94.

Look AHEAD Research Group; Gregg E, Jakicic J, Blackburn G et al (2016) Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 4(11):913–921. https://doi.org/10.1016/S2213-8587(16)30162-0

95.

Look AHEAD Research Group; Wing RR, Bray GA, Cassidy-Begay M et al Effects of intensive lifestyle intervention on all-cause mortality in older adults with type 2 diabetes and overweight/obesity: results from the Look AHEAD study. Diabetes Care 45(5):1252–1259. https://doi.org/10.2337/dc21-1805

96.

American Diabetes Association (2021) 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes – 2021. Diabetes Care 44(Supplement 1):S40–S52. https://doi.org/10.2337/dc21-S004CrossRef

97.

Lee SWH, Ng KY, Chin WK (2017) The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis. Sleep Med Rev 31:91–101. https://doi.org/10.1016/j.smrv.2016.02.001CrossRefPubMed

98.

Schipper SBJ, Van Veen MM, Elders PJM et al (2021) Sleep disorders in people with type 2 diabetes and associated health outcomes: a review of the literature. Diabetologia 64(11):2367–2377. https://doi.org/10.1007/s00125-021-05541-0CrossRefPubMedPubMedCentral

99.

Navarro DJ, Alpert PT, Cross C (2019) The impact of shift work on diabetes self-management activities. J Dr Nurs Pract 12(1):66–72. https://doi.org/10.1891/2380-9418.12.1.66CrossRefPubMed

100.

Henson J, Rowlands AV, Baldry E et al (2020) Physical behaviors and chronotype in people with type 2 diabetes. BMJ Open Diabetes Res Care 8(1):e001375. https://doi.org/10.1136/bmjdrc-2020-001375CrossRefPubMedPubMedCentral

101.

Kanaley JA, Colberg SR, Corcoran MH et al (2022) Exercise/physical activity in individuals with type 2 diabetes: a Consensus Statement from the American College of Sports Medicine. Med Sci Sports Exerc 54(2):353–368. https://doi.org/10.1249/MSS.0000000000002800CrossRefPubMed

102.

Bull FC, Al-Ansari SS, Biddle S et al (2020) World Health Organization 2020 guidelines on physical activity and sedentary behaviour. Br J Sports Med 54(24):1451–1462. https://doi.org/10.1136/bjsports-2020-102955CrossRefPubMed

103.

Homer AR, Taylor FC, Dempsey PC et al (2021) Frequency of interruptions to sitting time: benefits for postprandial metabolism in type 2 diabetes. Diabetes Care 44(6):1254–1263. https://doi.org/10.2337/dc20-1410CrossRefPubMedPubMedCentral

104.

Dempsey PC, Larsen RN, Sethi P et al (2016;dc152336) Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. Diabetes Care. https://doi.org/10.2337/dc15-2336

105.

Rowlands A, Davies M, Dempsey P, Edwardson C, Razieh C, Yates T (2021) Wrist-worn accelerometers: recommending ~1.0 mg as the minimum clinically important difference (MCID) in daily average acceleration for inactive adults. Br J Sports Med 55(14):814–815. https://doi.org/10.1136/bjsports-2020-102293CrossRefPubMed

106.

Yates T, Haffner SM, Schulte PJ et al (2014) Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. Lancet 383(9922):1059–1066. https://doi.org/10.1016/S0140-6736(13)62061-9

107.

Saint-Maurice PF, Troiano RP, Bassett DR et al (2020) Association of daily step count and step intensity with mortality among US adults. JAMA 323(12):1151–1160. https://doi.org/10.1001/jama.2020.1382CrossRefPubMedPubMedCentral

108.

Jayedi A, Emadi A, Shab-Bidar S Dose-dependent effect of supervised aerobic exercise on HbA_1c in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Sports Med 52(8):1919–1938. https://doi.org/10.1007/s40279-022-01673-4

109.

Chudasama YV, Khunti KK, Zaccardi F et al (2019) Physical activity, multimorbidity, and life expectancy: a UK Biobank longitudinal study. BMC Med 17(1):108. https://doi.org/10.1186/s12916-019-1339-0CrossRefPubMedPubMedCentral

110.

Pan B, Ge L, Xun YQ et al (2018) Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. Int J Behav Nutr Phys Act 15(1):72. https://doi.org/10.1186/s12966-018-0703-3CrossRefPubMedPubMedCentral

111.

Mickute M, Henson J, Rowlands AV et al (2021) Device-measured physical activity and its association with physical function in adults with type 2 diabetes mellitus. Diabet Med 38(6):e14393. https://doi.org/10.1111/dme.14393

112.

Ahmad E, Sargeant JA, Yates T, Webb DR, Davies MJ (2022) Type 2 diabetes and impaired physical function: a growing problem. Diabetology 3(1):30–45. https://doi.org/10.3390/diabetology3010003CrossRef

113.

Smyth A, Jenkins M, Dunham M, Kutzer Y, Taheri S, Whitehead L (2020) Systematic review of clinical practice guidelines to identify recommendations for sleep in type 2 diabetes mellitus management. Diabetes Res Clin Pract 170:108532. https://doi.org/10.1016/j.diabres.2020.108532CrossRefPubMed

114.

Zuraikat FM, Makarem N, Redline S, Aggarwal B, Jelic S, St-Onge MP (2020) Sleep regularity and cardiometabolic heath: is variability in sleep patterns a risk factor for excess adiposity and glycemic dysregulation? Curr Diab Rep 20(8):38. https://doi.org/10.1007/s11892-020-01324-wCrossRefPubMedPubMedCentral

115.

International Diabetes Federation (2017) The IDF Consensus Statement on sleep apnoea and type 2 diabetes. Available from www.idf.org/our-activities/advocacy-awareness/resources-and-tools/62-idf-consensus-statement-on-sleep-apnoea-and-type-2-diabetes.html. Accessed 5 Jun 2022

116.

Fallahi A, Jamil DI, Karimi EB, Baghi V, Gheshlagh RG (2019) Prevalence of obstructive sleep apnea in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Syndr 13(4):2463–2468. https://doi.org/10.1016/j.dsx.2019.06.030CrossRefPubMed

117.

Sondrup N, Termannsen AD, Eriksen JN et al (2022) Effects of sleep manipulation on markers of insulin sensitivity: a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 62:101594. https://doi.org/10.1016/j.smrv.2022.101594CrossRefPubMed

118.

Delevatti RS, Bracht CG, Lisboa SDC et al (2019) The role of aerobic training variables progression on glycemic control of patients with type 2 diabetes: a systematic review with meta-analysis. Sports Med - Open 5(1):22. https://doi.org/10.1186/s40798-019-0194-zCrossRefPubMedPubMedCentral

119.

Najafipour F, Mobasseri M, Yavari A et al (2017) Effect of regular exercise training on changes in HbA1c, BMI and VO2max among patients with type 2 diabetes mellitus: an 8-year trial. BMJ Open Diabetes Res Care 5(1):e000414. https://doi.org/10.1136/bmjdrc-2017-000414CrossRefPubMedPubMedCentral

120.

Borror A, Zieff G, Battaglini C, Stoner L (2018) The effects of postprandial exercise on glucose control in individuals with type 2 diabetes: a systematic review. Sports Med Auckl NZ 48(6):1479–1491. https://doi.org/10.1007/s40279-018-0864-xCrossRef

121.

Guo S, Xu Y, Qin J et al (2021) Effect of tai chi on glycaemic control, lipid metabolism and body composition in adults with type 2 diabetes: a meta-analysis and systematic review. J Rehabil Med 53(3):jrm00165. https://doi.org/10.2340/16501977-2799CrossRefPubMed

122.

Gupta U, Gupta Y, Jose D et al (2020) Effectiveness of yoga-based exercise program compared to usual care, in improving HbA_1c in individuals with type 2 diabetes: a randomized control trial. Int J Yoga 13(3):233–238. https://doi.org/10.4103/ijoy.IJOY_33_20CrossRefPubMedPubMedCentral

123.

de Mello MB, Righi NC, Schuch FB, Signori LU, da Silva AMV (2021) Effect of high-intensity interval training protocols on VO2max and HbA1c level in people with type 2 diabetes: a systematic review and meta-analysis. Ann Phys Rehabil Med 65(5):101586. https://doi.org/10.1016/j.rehab.2021.101586CrossRefPubMed

124.

American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G et al (2022) 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S46–S59. https://doi.org/10.2337/dc22-S004

125.

Tasali E, Wroblewski K, Kahn E, Kilkus J, Schoeller DA (2022) Effect of sleep extension on objectively assessed energy intake among adults with overweight in real-life settings: a randomized clinical trial. JAMA Intern Med 182(4):365–374. https://doi.org/10.1001/jamainternmed.2021.8098CrossRefPubMedPubMedCentral

126.

Depner CM, Melanson EL, Eckel RH et al (2019) Ad libitum weekend recovery sleep fails to prevent metabolic dysregulation during a repeating pattern of insufficient sleep and weekend recovery sleep. Curr Biol 29(6):957–967.e4. https://doi.org/10.1016/j.cub.2019.01.069CrossRefPubMed

127.

American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G et al (2022) 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S113–S124. https://doi.org/10.2337/dc22-S008

128.

Davies M, Færch L, Jeppesen OK et al (2021) Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971–984. https://doi.org/10.1016/S0140-6736(21)00213-0

129.

Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989–1002. https://doi.org/10.1056/NEJMoa2032183CrossRefPubMed

130.

Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387(3):205–216. https://doi.org/10.1056/NEJMoa2206038CrossRefPubMed

131.

Rubino D, Abrahamsson N, Davies M et al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14):1414–1425. https://doi.org/10.1001/jama.2021.3224CrossRefPubMed

132.

Rubino F, Nathan DM, Eckel RH et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by International Diabetes Organizations. Diabetes Care 39(6):861–877. https://doi.org/10.2337/dc16-0236CrossRefPubMed

133.

Carmona MN, Santos-Sousa H, Lindeza L et al (2021) Comparative effectiveness of bariatric surgeries in patients with type 2 diabetes mellitus and BMI ≥ 25 kg/m2: a systematic review and network meta-analysis. Obes Surg 31(12):5312–5321. https://doi.org/10.1007/s11695-021-05725-yCrossRefPubMed

134.

Currie AC, Askari A, Fangueiro A, Mahawar K (2021) Network meta-analysis of metabolic surgery procedures for the treatment of obesity and diabetes. Obes Surg 31(10):4528–4541. https://doi.org/10.1007/s11695-021-05643-zCrossRefPubMedPubMedCentral

135.

Cresci B, Cosentino C, Monami M, Mannucci E (2020) Metabolic surgery for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Diabetes Obes Metab 22(8):1378–1387. https://doi.org/10.1111/dom.14045CrossRefPubMed

136.

Rubio-Almanza M, Hervás-Marín D, Cámara-Gómez R, Caudet-Esteban J, Merino-Torres JF (2019) Does metabolic surgery lead to diabetes remission in patients with BMI <30 kg/m²?: a meta-analysis. Obes Surg 29(4):1105–1116. https://doi.org/10.1007/s11695-018-03654-x

137.

Khorgami Z, Shoar S, Saber AA, Howard CA, Danaei G, Sclabas GM (2019) Outcomes of bariatric surgery versus medical management for type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Obes Surg 29(3):964–974. https://doi.org/10.1007/s11695-018-3552-xCrossRefPubMed

138.

Fultang J, Chinaka U, Rankin J, Bakhshi A, Ali A Preoperative bariatric surgery predictors of type 2 diabetes remission. J Obes Metab Syndr 30(2):104–114. https://doi.org/10.20517/cdr.2020.106

139.

Mingrone G, Panunzi S, De Gaetano A et al (2021) Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 397(10271):293–304. https://doi.org/10.1016/S0140-6736(20)32649-0

140.

Aminian A, Kashyap SR, Wolski KE et al (2021) Patient-reported outcomes after metabolic surgery versus medical therapy for diabetes: insights from the STAMPEDE randomized trial. Ann Surg 274(3):524–532. https://doi.org/10.1097/SLA.0000000000005003CrossRefPubMed

141.

American Diabetes Association Professional Practice Committee (2022) 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes – 2022. Diabetes Care 45(Suppl 1):S144–S174. https://doi.org/10.2337/dc22-S010CrossRef

142.

McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 6(2):148–158. https://doi.org/10.1001/jamacardio.2020.4511CrossRefPubMed

143.

Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720CrossRefPubMed

144.

Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657. https://doi.org/10.1056/NEJMoa1611925CrossRefPubMed

145.

Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347–357. https://doi.org/10.1056/NEJMoa1812389CrossRefPubMed

146.

Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383(15):1425–1435. https://doi.org/10.1056/NEJMoa2004967CrossRefPubMed

147.

Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384(2):129–139. https://doi.org/10.1056/NEJMoa2030186CrossRefPubMed

148.

McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303CrossRefPubMed

149.

Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413–1424. https://doi.org/10.1056/NEJMoa2022190CrossRefPubMed

150.

Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384(2):117–128. https://doi.org/10.1056/NEJMoa2030183CrossRefPubMed

151.

Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451–1461. https://doi.org/10.1056/NEJMoa2107038CrossRefPubMed

152.

Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744CrossRefPubMed

153.

Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446. https://doi.org/10.1056/NEJMoa2024816CrossRefPubMed

154.

Boehringer Ingelheim (2022) Prescribing information for JARDIANCE. Available from https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf. Accessed 20 Jun 2022

155.

Janssen (2020) Prescribing information for INVOKANA. Available from www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVOKANA-pi.pdf. Accessed 20 Jun 2022

156.

(2021) Prescribing information for FARXIGA. Available from https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/0be9cb1b-3b33-41c7-bfc2-04c9f718e442/0be9cb1b-3b33-41c7-bfc2-04c9f718e442_viewable_rendition__v.pdf. Accessed 20 Jun 2022

157.

Merck (2017) Prescribing information for STEGLATRO. Available from www.accessdata.fda.gov/drugsatfda_docs/label/2017/209803s000lbl.pdf. Accessed 20 Jun 2022

158.

Mistry S, Eschler DC (2021) Euglycemic Diabetic Ketoacidosis Caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. AACE Clin Case Rep 7(1):17–19. https://doi.org/10.1016/j.aace.2020.11.009CrossRefPubMed

159.

Kosiborod MN, Esterline R, Furtado RHM et al (2021) Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 9(9):586–594. https://doi.org/10.1016/S2213-8587(21)00180-7CrossRefPubMedPubMedCentral

160.

Qian BB, Chen Q, Li L, Yan CF (2020) Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporos Int 31(12):2313–2320. https://doi.org/10.1007/s00198-020-05590-y

161.

Dorsey-Treviño EG, González-González JG, Alvarez-Villalobos N et al (2020) Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Investig 43(3):289–304. https://doi.org/10.1007/s40618-019-01103-9CrossRef

162.

Barraclough JY, Yu J, Figtree GA et al (2022) Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab 24(6):1072–1083. https://doi.org/10.1111/dom.14671CrossRefPubMed

163.

Heerspink HJL, Oshima M, Zhang H et al (2022) Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial. Am J Kidney Dis 79(2):244–256.e1. https://doi.org/10.1053/j.ajkd.2021.05.005

164.

Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab 46:101102. https://doi.org/10.1016/j.molmet.2020.101102CrossRefPubMed

165.

Novo Nordisk (2019) Prescribing information for RYBELSUS. Available from www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf. Accessed 20 Jun 2022

166.

Frias JP, Bonora E, Nevarez Ruiz L et al (2021) Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care 44(3):765–773. https://doi.org/10.2337/dc20-1473CrossRefPubMedPubMedCentral

167.

Frías JP, Auerbach P, Bajaj HS et al (2021) Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol 9(9):563–574. https://doi.org/10.1016/S2213-8587(21)00174-1CrossRefPubMed

168.

Wharton S, Davies M, Dicker D et al (2022) Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med 134(1):14–19. https://doi.org/10.1080/00325481.2021.2002616CrossRefPubMed

169.

Peng H, Want LL, Aroda VR (2016) Safety and tolerability of glucagon-like peptide-1 receptor agonists utilizing data from the exenatide clinical trial development program. Curr Diab Rep 16(5):44. https://doi.org/10.1007/s11892-016-0728-4CrossRefPubMed

170.

Vilsbøll T, Bain SC, Leiter LA et al (2018) Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20(4):889–897. https://doi.org/10.1111/dom.13172CrossRefPubMedPubMedCentral

171.

Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC (2021) HbA_1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 44(1):290–296. https://doi.org/10.2337/dc20-1815

172.

He L, Wang J, Ping F et al (2022) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 182(5):513–519. https://doi.org/10.1001/jamainternmed.2022.0338CrossRefPubMed

173.

Crowley MJ, McGuire DK, Alexopoulos AS et al (2020) Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial. Diabetes Care 43(9):e108–e110. https://doi.org/10.2337/dc20-0437CrossRefPubMedPubMedCentral

174.

Neuen BL, Arnott C, Perkovic V et al (2021) Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. Diabetes Obes Metab 23(2):382–390. https://doi.org/10.1111/dom.14226CrossRefPubMed

175.

Masson W, Lavalle-Cobo A, Lobo M, Masson G, Molinero G (2021) Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. Eur J Prev Cardiol 28(1):69–75. https://doi.org/10.1093/eurjpc/zwaa074CrossRefPubMed

176.

Matthews D, Del Prato S, Mohan V et al (2020) Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type 2 diabetes. Diabetes Ther 11(11):2465–2476. https://doi.org/10.1007/s13300-020-00926-7

177.

Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, Broe MED (2018) Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. Diabetes Care 41(3):547–553. https://doi.org/10.2337/dc17-2231CrossRefPubMed

178.

Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA (2018) Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3year trial. J Diabetes Complicat 32(2):171–178. https://doi.org/10.1016/j.jdiacomp.2017.11.001CrossRef

179.

Aroda VR, Edelstein SL, Goldberg RB et al (2016) Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 101(4):1754–1761. https://doi.org/10.1210/jc.2015-3754CrossRefPubMedPubMedCentral

180.

Perkovic V, Toto R, Cooper ME et al (2020) Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care 43(8):1803–1812. https://doi.org/10.2337/dc20-0279CrossRefPubMedPubMedCentral

181.

Umpierrez GE, Cardona S, Chachkhiani D et al (2018) A randomized controlled study comparing a DPP4 inhibitor (linagliptin) and basal insulin (glargine) in patients with type 2 diabetes in long-term care and skilled nursing facilities: Linagliptin-LTC trial. J Am Med Dir Assoc 19(5):399–404.e3. https://doi.org/10.1016/j.jamda.2017.11.002CrossRefPubMed

182.

Batule S, Ramos A, Pérez-Montes de Oca A et al (2022) Comparison of glycemic variability and hypoglycemic events in hospitalized older adults treated with basal insulin plus vildagliptin and basal-bolus insulin regimen: a prospective randomized study. J Clin Med 11(10):2813. https://doi.org/10.3390/jcm11102813CrossRefPubMedPubMedCentral

183.

Rosenstock J, Wysham C, Frías JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398(10295):143–155. https://doi.org/10.1016/S0140-6736(21)01324-6

184.

Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327(6):534–545. https://doi.org/10.1001/jama.2022.0078CrossRefPubMedPubMedCentral

185.

Frías JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503–515. https://doi.org/10.1056/NEJMoa2107519CrossRefPubMed

186.

Ludvik B, Giorgino F, Jódar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398(10300):583–598. https://doi.org/10.1016/S0140-6736(21)01443-4

187.

Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398(10313):1811–1824. https://doi.org/10.1016/S0140-6736(21)02188-7

188.

Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10(6):393–406. https://doi.org/10.1016/S2213-8587(22)00070-5CrossRefPubMed

189.

Karagiannis T, Avgerinos I, Liakos A et al (2022) Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 65(8):1251–1261. https://doi.org/10.1007/s00125-022-05715-4CrossRefPubMedPubMedCentral

190.

Sattar N, McGuire DK, Pavo I et al (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28(3):591–598. https://doi.org/10.1038/s41591-022-01707-4CrossRefPubMedPubMedCentral

191.

Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ (2018) Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol 6(10):821–832. https://doi.org/10.1016/S2213-8587(18)30025-1CrossRefPubMed

192.

UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853. https://doi.org/10.1016/S0140-6736(98)07019-6CrossRef

193.

Vaccaro O, Masulli M, Nicolucci A et al (2017) Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 5(11):887–897. https://doi.org/10.1016/S2213-8587(17)30317-0CrossRefPubMed

194.

Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322(12):1155–1166. https://doi.org/10.1001/jama.2019.13772CrossRefPubMedPubMedCentral

195.

Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321(1):69–79. https://doi.org/10.1001/jama.2018.18269CrossRefPubMed

196.

Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355(23):2427–2443. https://doi.org/10.1056/NEJMoa066224CrossRefPubMed

197.

Dormandy JA, Charbonnel B, Eckland DJA et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493):1279–1289. https://doi.org/10.1016/S0140-6736(05)67528-9

198.

Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374(14):1321–1331. https://doi.org/10.1056/NEJMoa1506930CrossRefPubMedPubMedCentral

199.

Spence JD, Viscoli CM, Inzucchi SE et al (2019) Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. JAMA Neurol 76(5):526–535. https://doi.org/10.1001/jamaneurol.2019.0079CrossRefPubMedPubMedCentral

200.

Cusi K, Orsak B, Bril F et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med 165(5):305–315. https://doi.org/10.7326/M15-1774CrossRefPubMed

201.

Della Pepa G, Russo M, Vitale M et al (2021) Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract 178:108984. https://doi.org/10.1016/j.diabres.2021.108984CrossRefPubMed

202.

Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373(9681):2125–2135. https://doi.org/10.1016/S0140-6736(09)60953-3

203.

Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27(1):141–147. https://doi.org/10.2337/diacare.27.1.141CrossRefPubMed

204.

Viscoli CM, Inzucchi SE, Young LH et al (2017) Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. J Clin Endocrinol Metab 102(3):914–922. https://doi.org/10.1210/jc.2016-3237CrossRefPubMed

205.

Kahn SE, Zinman B, Lachin JM et al (2008) Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31(5):845–851. https://doi.org/10.2337/dc07-2270CrossRefPubMed

206.

DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE (2019) Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res 16(2):133–143. https://doi.org/10.1177/1479164118825376CrossRefPubMed

207.

Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377(8):723–732. https://doi.org/10.1056/NEJMoa1615692CrossRefPubMedPubMedCentral

208.

ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367(4):319–328. https://doi.org/10.1056/NEJMoa1203858CrossRef

209.

Lowe RN, Williams B, Claus LW (2022) Diabetes: how to manage patients experiencing hypoglycaemia. Drugs Context 11:2021-9-11. https://doi.org/10.3389/fmicb.2022.863129CrossRefPubMedPubMedCentral

210.

Mannucci E, Caiulo C, Naletto L, Madama G, Monami M (2021) Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. Endocrine 74(3):508–517. https://doi.org/10.1007/s12020-021-02889-6CrossRefPubMed

211.

Chan J, Cheng-Lai A (2017) Inhaled insulin: a clinical and historical review. Cardiol Rev 25(3):140–146. https://doi.org/10.1097/CRD.0000000000000143CrossRefPubMed

212.

Bergenstal RM, Peyrot M, Dreon DM et al (2019) Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. Diabetes Technol Ther 21(5):273–285. https://doi.org/10.1089/dia.2018.0298CrossRefPubMedPubMedCentral

213.

Heinemann L, Parkin CG (2018) Rethinking the viability and utility of inhaled insulin in clinical practice. J Diabetes Res 2018:4568903. https://doi.org/10.1155/2018/4568903CrossRefPubMedPubMedCentral

214.

Aroda VR, Arulandu JR, Cannon AJ (2018) Insulin/glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one? Clin Diabetes 36(2):138–147. https://doi.org/10.2337/cd17-0065CrossRefPubMedPubMedCentral

215.

Maiorino MI, Chiodini P, Bellastella G et al (2018) Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 20(9):2309–2313. https://doi.org/10.1111/dom.13343CrossRefPubMed

216.

Blonde L, Rosenstock J, Del Prato S et al (2019) Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G Randomized Clinical Trial. Diabetes Care 42(11):2108–2116. https://doi.org/10.2337/dc19-1357CrossRefPubMed

217.

Linjawi S, Bode BW, Chaykin LB et al (2017) The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial. Diabetes Ther 8(1):101–114. https://doi.org/10.1007/s13300-016-0218-3CrossRefPubMed

218.

Aroda VR, Rosenstock J, Wysham C et al (2016) Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. Diabetes Care 39(11):1972–1980. https://doi.org/10.2337/dc16-1495CrossRefPubMed

219.

Lingvay I, Manghi FP, García-Hernández P et al (2016) Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315(9):898–907. https://doi.org/10.1001/jama.2016.1252CrossRefPubMed

220.

Buse JB, Vilsbøll T, Thurman J et al (2014) Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care 37(11):2926–2933. https://doi.org/10.2337/dc14-0785CrossRefPubMed

221.

Kasthuri S, Poongothai S, Anjana RM et al (2021) Comparison of glycemic excursion using flash continuous glucose monitoring in patients with type 2 diabetes mellitus before and after treatment with voglibose. Diabetes Technol Ther 23(3):213–220. https://doi.org/10.1089/dia.2019.0484CrossRefPubMedPubMedCentral

222.

Dalsgaard NB, Gasbjerg LS, Hansen LS et al (2021) The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. Eur J Endocrinol 184(3):383–394. https://doi.org/10.1530/EJE-20-1121CrossRefPubMed

223.

Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 173(4):278–286. https://doi.org/10.7326/M20-0864CrossRefPubMed

224.

Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab 23(9):2116–2124. https://doi.org/10.1111/dom.14451CrossRefPubMed

225.

Abdul-Ghani M, Puckett C, Adams J et al (2021) Durability of triple combination therapy versus stepwise addition therapy in patients with new-onset T2DM: 3-year follow-up of EDICT. Diabetes Care 44(2):433–439. https://doi.org/10.2337/dc20-0978CrossRefPubMed

226.

Matthews DR, Paldánius PM, Proot P et al (2019) Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 394(10208):1519–1529. https://doi.org/10.1016/S0140-6736(19)32131-2

227.

Aroda VR, González-Galvez G, Grøn R et al (2019) Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 7(8):596–605. https://doi.org/10.1016/S2213-8587(19)30184-6CrossRefPubMed

228.

Mantsiou C, Karagiannis T, Kakotrichi P et al (2020) Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22(10):1857–1868. https://doi.org/10.1111/dom.14108CrossRefPubMed

229.

Li C, Luo J, Jiang M, Wang K (2022) The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol 13:838277. https://doi.org/10.3389/fphar.2022.887833CrossRefPubMedPubMedCentral

230.

Guo M, Gu J, Teng F et al (2020) The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine 67(2):294–304. https://doi.org/10.1007/s12020-019-02175-6CrossRefPubMed

231.

Eng C, Kramer CK, Zinman B, Retnakaran R (2014) Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 384(9961):2228–2234. https://doi.org/10.1016/S0140-6736(14)61335-0

232.

Li D, Shi W, Wang T, Tang H (2018) SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 20(8):1972–1976. https://doi.org/10.1111/dom.13294CrossRefPubMed

233.

Chenchula S, Varthya SB, Padmavathi R (2022) Rationality, efficacy, tolerability of empagliflozin plus linagliptin combination for the management of type 2 diabetes mellitus: a systematic review of randomized controlled trials and observational studies. Curr Diabetes Rev 18(4):e100921196392. https://doi.org/10.2174/1573399817666210910165402CrossRefPubMed

234.

Katsiki N, Ofori-Asenso R, Ferrannini E, Mazidi M (2020) Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 22(6):1001–1005. https://doi.org/10.1111/dom.13989CrossRefPubMed

235.

Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM (2018) Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis. Sci Rep 8(1):4466. https://doi.org/10.1038/s41598-018-22658-2CrossRefPubMedPubMedCentral

236.

Milder TY, Stocker SL, Abdel Shaheed C et al (2019) Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis. J Clin Med 8(1):E45. https://doi.org/10.3390/jcm8010045CrossRefPubMed

237.

Castellana M, Cignarelli A, Brescia F, Laviola L, Giorgino F (2019) GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev 35(1):e3082. https://doi.org/10.1002/dmrr.3082CrossRefPubMed

238.

Min SH, Yoon JH, Hahn S, Cho YM (2018) Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: a systematic review with meta-analysis. J Diabetes Investig 9(4):893–902. https://doi.org/10.1111/jdi.12754CrossRefPubMed

239.

Cai X, Gao X, Yang W, Han X, Ji L (2018) Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: a systematic review and meta-analysis. Diabetes Ther Res Treat Educ Diabetes Relat Disord 9(5):1995–2014. https://doi.org/10.1007/s13300-018-0493-2CrossRef

240.

Dave CV, Kim SC, Goldfine AB, Glynn RJ, Tong A, Patorno E (2021) Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA Therapy. Circulation 143(8):770–779. https://doi.org/10.1161/CIRCULATIONAHA.120.047965CrossRefPubMed

241.

Lam CSP, Ramasundarahettige C, Branch KRH et al (2022) Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation 145(8):565–574. https://doi.org/10.1161/CIRCULATIONAHA.121.057934CrossRefPubMed

242.

DeFronzo RA (2017) Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 19(10):1353–1362. https://doi.org/10.1111/dom.12982CrossRefPubMedPubMedCentral

243.

Wright AK, Carr MJ, Kontopantelis E et al (2022) Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 45(4):909–918. https://doi.org/10.2337/dc21-1113CrossRefPubMed

244.

Clegg LE, Penland RC, Bachina S et al (2019) Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovasc Diabetol 18(1):138. https://doi.org/10.1186/s12933-019-0942-xCrossRefPubMedPubMedCentral

245.

Nathan DM (2022) Glycemic Outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study. N Engl J Med. https://doi.org/10.1056/NEJMoa2200433

246.

Nathan DM (2022) Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes. N Engl J Med. https://doi.org/10.1056/NEJMoa2200436

247.

Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385(10):896–907. https://doi.org/10.1056/NEJMoa2108269CrossRefPubMed

248.

Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS (2022) Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med 28(1):89–95. https://doi.org/10.1038/s41591-021-01584-3CrossRefPubMed

249.

Giugliano D, Longo M, Caruso P, Maiorino MI, Bellastella G, Esposito K (2021) Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis. Diabetes Obes Metab 23(7):1672–1676. https://doi.org/10.1111/dom.14374CrossRefPubMed

250.

Lee MMY, Kristensen SL, Gerstein HC, McMurray JJV, Sattar N (2022) Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes Metab Syndr 16(1):102382. https://doi.org/10.1016/j.dsx.2021.102382CrossRefPubMed

251.

Shaman AM, Bain SC, Bakris GL et al (2022) Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145(8):575–585. https://doi.org/10.1161/CIRCULATIONAHA.121.055459CrossRefPubMed

252.

Neuen BL, Young T, Heerspink HJL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845–854. https://doi.org/10.1016/S2213-8587(19)30256-6CrossRefPubMed

253.

Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653–662. https://doi.org/10.1016/S2213-8587(21)00203-5CrossRefPubMed

254.

Tsai WH, Chuang SM, Liu SC et al (2021) Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis. Sci Rep 11(1):15364. https://doi.org/10.1038/s41598-021-94945-4CrossRefPubMedPubMedCentral

255.

Strain WD, Frenkel O, James MA et al (2022) Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. Stroke. https://doi.org/10.1161/STROKEAHA.121.037775

256.

Tsapas A, Karagiannis T, Avgerinos I, Liakos A, Bekiari E (2021) GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Res Clin Pract 177:108921. https://doi.org/10.1016/j.diabres.2021.108921CrossRefPubMed

257.

Lavalle-Cobo A, Masson W, Lobo M, Masson G, Molinero G (2021) Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis. High Blood Press Cardiovasc Prev 28(6):605–612. https://doi.org/10.1007/s40292-021-00479-1

258.

Husain M, Consoli A, De Remigis A, Pettersson Meyer AS, Rasmussen S, Bain S (2022) Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovasc Diabetol 21(1):64. https://doi.org/10.1186/s12933-022-01489-6CrossRefPubMedPubMedCentral

259.

Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573. https://doi.org/10.1136/bmj.m4573CrossRefPubMedPubMedCentral

260.

Lin DSH, Lee JK, Hung CS, Chen WJ (2021) The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia 64(12):2676–2686. https://doi.org/10.1007/s00125-021-05529-wCrossRefPubMed

261.

Patorno E, Htoo PT, Glynn RJ et al (2021) Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med 174(11):1528–1541. https://doi.org/10.7326/M21-0893CrossRefPubMedPubMedCentral

262.

Bahour N, Cortez B, Pan H, Shah H, Doria A, Aguayo-Mazzucato C (2022) Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers. GeroScience 44(1):415–427. https://doi.org/10.1007/s11357-021-00469-0CrossRefPubMed

263.

Nguyen TN, Harris K, Woodward M et al (2021) The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. Diabetes Care 44(7):1622–1629. https://doi.org/10.2337/dc20-2664CrossRefPubMedPubMedCentral

264.

European Medicines Agency (EMA) (2012) Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available from www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf. Accessed 18 Aug 2022

265.

Food and Drug Administration (2008) Draft guidance for industry on diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention – guidance document Available from www.regulations.gov/document/FDA-2008-D-0118-0003. Accessed 22 Jun 2022

266.

Karagiannis T, Tsapas A, Athanasiadou E et al (2021) GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 174:108737. https://doi.org/10.1016/j.diabres.2021.108737CrossRefPubMed

267.

Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G (2020) Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016. JAMA Pediatr 174(2):e194498. https://doi.org/10.1001/jamapediatrics.2019.4498CrossRefPubMed

268.

Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA et al (2007) Incidence of diabetes in youth in the United States. JAMA 297(24):2716–2724. https://doi.org/10.1001/jama.297.24.2716CrossRef

269.

RISE Consortium (2018) Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 41(8):1717–1725. https://doi.org/10.2337/dc18-0787CrossRef

270.

RISE Consortium (2019) Lack of Durable improvements in β-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 42(9):1742–1751. https://doi.org/10.2337/dc19-0556CrossRef

271.

Hannon TS, Arslanian SA (2015) The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes. Ann N Y Acad Sci 1353(1):113–137. https://doi.org/10.1111/nyas.12939CrossRefPubMed

272.

TODAY Study Group (2013) Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 36(6):1749–1757. https://doi.org/10.2337/dc12-2393CrossRefPubMedCentral

273.

Jalaludin MY, Deeb A, Zeitler P et al (2022) Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatr Diabetes 23(2):183–193. https://doi.org/10.1111/pedi.13282CrossRefPubMed

274.

TODAY Study Group, Bjornstad P, Drews KL et al (2021) Long-term complications in youth-onset type 2 diabetes. N Engl J Med 385(5):416–426. https://doi.org/10.1056/NEJMoa2100165CrossRefPubMedCentral

275.

Gregg EW, Hora I, Benoit SR (2019) Resurgence in diabetes-related complications. JAMA 321(19):1867–1868. https://doi.org/10.1001/jama.2019.3471CrossRefPubMed

276.

Chan JCN, Paldánius PM, Mathieu C, Stumvoll M, Matthews DR, Del Prato S (2021) Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. Diabetes Obes Metab 23(1):245–251. https://doi.org/10.1111/dom.14192CrossRefPubMed

277.

Bhattarai M, Salih M, Regmi M et al (2022) Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis. JAMA Netw Open 5(1):e2142078. https://doi.org/10.1001/jamanetworkopen.2021.42078CrossRefPubMedPubMedCentral

278.

Mishriky BM, Powell JR, Wittwer JA et al (2019) Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes Obes Metab 21(10):2274–2283. https://doi.org/10.1111/dom.13805CrossRefPubMed

279.

US Food and Drug Administration (2022) Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry; availability. Available from www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-plans-improve-enrollment-participants-underrepresented-racial-and-ethnic-populations. Accessed 22 Jun 2022.

280.

Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S14–S21. https://doi.org/10.1007/pl00002934CrossRefPubMed

281.

Regensteiner JG, Golden S, Huebschmann AG et al (2015) Sex differences in the cardiovascular consequences of diabetes mellitus: a Scientific Statement From the American Heart Association. Circulation 132(25):2424–2447. https://doi.org/10.1161/CIR.0000000000000343CrossRefPubMed

282.

Kannel WB, Wilson PW (1995) Risk factors that attenuate the female coronary disease advantage. Arch Intern Med 155(1):57–61. https://doi.org/10.1001/archinte.1995.00430010063008CrossRefPubMed

283.

Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J (2005) Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Diabetologia 48(5):856–861. https://doi.org/10.1007/s00125-005-1730-6CrossRefPubMed

284.

Peters SAE, Huxley RR, Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 383(9933):1973–1980. https://doi.org/10.1016/S0140-6736(14)60040-4

285.

Peters SAE, Huxley RR, Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 57(8):1542–1551. https://doi.org/10.1007/s00125-014-3260-6CrossRefPubMed

286.

Peters SAE, Woodward M (2018) Sex differences in the burden and complications of diabetes. Curr Diab Rep 18(6):33. https://doi.org/10.1007/s11892-018-1005-5CrossRefPubMedPubMedCentral

287.

Clemens KK, Woodward M, Neal B, Zinman B (2020) Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis. Diabetes Care 43(5):1157–1163. https://doi.org/10.2337/dc19-2257CrossRefPubMed

288.

Singh AK, Singh R (2020) Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes Metab Syndr 14(3):181–187. https://doi.org/10.1016/j.dsx.2020.02.012CrossRefPubMed

289.

Rådholm K, Zhou Z, Clemens K, Neal B, Woodward M (2020) Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men. Diabetes Obes Metab 22(2):263–266. https://doi.org/10.1111/dom.13876CrossRefPubMed

290.

Lazarus JV, Mark HE, Anstee QM et al (2022) Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 19(1):60–78. https://doi.org/10.1038/s41575-021-00523-4CrossRefPubMed

291.

Kanwal F, Shubrook JH, Adams LA et al (2021) Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 161(5):1657–1669. https://doi.org/10.1053/j.gastro.2021.07.049CrossRefPubMed

292.

Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113–1124. https://doi.org/10.1056/NEJMoa2028395CrossRefPubMed

293.

Musso G, Cassader M, Paschetta E, Gambino R (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med 177(5):633–640. https://doi.org/10.1001/jamainternmed.2016.9607CrossRefPubMedPubMedCentral

294.

Panunzi S, Maltese S, Verrastro O et al (2021) Pioglitazone and bariatric surgery are the most effective treatments for non-alcoholic steatohepatitis: a hierarchical network meta-analysis. Diabetes Obes Metab 23(4):980–990. https://doi.org/10.1111/dom.14304CrossRefPubMed

295.

Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G (2020) Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab 46(6):427–441. https://doi.org/10.1016/j.diabet.2019.12.007CrossRefPubMed

296.

Lassailly G, Caiazzo R, Ntandja-Wandji LC et al (2020) Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 159(4):1290–1301.e5. https://doi.org/10.1053/j.gastro.2020.06.006CrossRefPubMed

297.

Russo MF, Lembo E, Mari A et al (2021) Insulin resistance is central to long-term reversal of histologic nonalcoholic steatohepatitis after metabolic surgery. J Clin Endocrinol Metab 106(3):750–761. https://doi.org/10.1210/clinem/dgaa892CrossRefPubMed

298.

Hartman ML, Sanyal AJ, Loomba R et al (2020) Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43(6):1352–1355. https://doi.org/10.2337/dc19-1892CrossRefPubMedPubMedCentral

299.

Ghosal S, Datta D, Sinha B (2021) A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep 11(1):22063. https://doi.org/10.1038/s41598-021-01663-yCrossRefPubMedPubMedCentral

300.

Coelho FDS, Borges-Canha M, von Hafe M et al (2021) Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 37(6):e3413. https://doi.org/10.1002/dmrr.3413CrossRefPubMed

301.

Dwinata M, Putera DD, Hasan I, Raharjo M (2020) SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. Clin Exp Hepatol 6(4):339–346. https://doi.org/10.5114/ceh.2020.102173CrossRefPubMedPubMedCentral

302.

Shao SC, Kuo LT, Chien RN, Hung MJ, Lai ECC (2020) SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews. BMJ Open Diabetes Res Care 8(2):e001956. https://doi.org/10.1136/bmjdrc-2020-001956CrossRefPubMedPubMedCentral

303.

Bril F, Cusi K (2017) Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action. Diabetes Care 40(3):419–430. https://doi.org/10.2337/dc16-1787CrossRefPubMed

304.

Wojeck BS, Inzucchi SE, Neeland IJ et al (2022) Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. Sleep Breath. https://doi.org/10.1007/s11325-022-02594-2

305.

Neeland IJ, Eliasson B, Kasai T et al (2020) The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial. Diabetes Care 43(12):3007–3015. https://doi.org/10.2337/dc20-1096CrossRefPubMedPubMedCentral

306.

Levengood TW, Peng Y, Xiong KZ et al (2019) Team-based care to improve diabetes management: a community guide meta-analysis. Am J Prev Med 57(1):e17–e26. https://doi.org/10.1016/j.amepre.2019.02.005CrossRefPubMedPubMedCentral

307.

Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ (2009) Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 52(10):2001–2014. https://doi.org/10.1007/s00125-009-1454-0CrossRefPubMedPubMedCentral

308.

Srikanth V, Sinclair AJ, Hill-Briggs F, Moran C, Biessels GJ (2020) Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol 8(6):535–545. https://doi.org/10.1016/S2213-8587(20)30118-2CrossRefPubMed

309.

Palta P, Schneider ALC, Biessels GJ, Touradji P, Hill-Briggs F (2014) Magnitude of cognitive dysfunction in adults with type 2 diabetes: a meta-analysis of six cognitive domains and the most frequently reported neuropsychological tests within domains. J Int Neuropsychol Soc 20(3):278–291. https://doi.org/10.1017/S1355617713001483CrossRefPubMedPubMedCentral

310.

Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 42(5):731–754. https://doi.org/10.2337/dci19-0014CrossRefPubMedPubMedCentral

311.

Centers for Disease Control and Prevention (2019) Writing SMART objectives. Available from www.cdc.gov/dhdsp/evaluation_resources/guides/writing-smart-objectives.htm. Accessed 22 Jun 2022

312.

Pi-Sunyer X (2014) The Look AHEAD trial: a review and discussion of its outcomes. Curr Nutr Rep 3(4):387–391. https://doi.org/10.1007/s13668-014-0099-xCrossRefPubMedPubMedCentral

313.

Cahn A, Raz I, Leiter LA et al (2021) Cardiovascular, renal, and metabolic outcomes of dapagliflozin versus placebo in a primary cardiovascular prevention cohort: analyses from DECLARE-TIMI 58. Diabetes Care 44(5):1159–1167. https://doi.org/10.2337/dc20-2492CrossRefPubMed

314.

Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311–322. https://doi.org/10.1056/NEJMoa1603827CrossRefPubMedPubMedCentral

315.

Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3

316.

Kahl S, Ofstad AP, Zinman B et al (2022) Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes Obes Metab 24(6):1061–1071. https://doi.org/10.1111/dom.14670CrossRefPubMed

317.

Brownrigg JRW, Hughes CO, Burleigh D et al (2016) Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol 4(7):588–597. https://doi.org/10.1016/S2213-8587(16)30057-2CrossRefPubMed

318.

Mearns ES, Saulsberry WJ, White CM et al (2015) Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis. Diabet Med 32(12):1530–1540. https://doi.org/10.1111/dme.12837CrossRefPubMed

319.

Zaccardi F, Dhalwani NN, Dales J et al (2018) Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Obes Metab 20(4):985–997. https://doi.org/10.1111/dom.13185CrossRefPubMed

320.

Downes MJ, Bettington EK, Gunton JE, Turkstra E (2015) Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ 3:e1461. https://doi.org/10.7717/peerj.1461CrossRefPubMedPubMedCentral

321.

Lee CMY, Woodward M, Colagiuri S (2016) Triple therapy combinations for the treatment of type 2 diabetes – A network meta-analysis. Diabetes Res Clin Pract 116:149–158. https://doi.org/10.1016/j.diabres.2016.04.037CrossRefPubMed

322.

Lukashevich V, Del Prato S, Araga M, Kothny W (2014) Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab 16(5):403–409. https://doi.org/10.1111/dom.12229CrossRefPubMed

323.

Hong AR, Lee J, Ku EJ et al (2015) Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res Clin Pract 109(1):141–148. https://doi.org/10.1016/j.diabres.2015.04.019CrossRefPubMed

324.

Moses RG, Kalra S, Brook D et al (2014) A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab 16(5):443–450. https://doi.org/10.1111/dom.12234CrossRefPubMed

325.

Moses RG, Round E, Shentu Y et al (2016) A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes 8(5):701–711. https://doi.org/10.1111/1753-0407.12351CrossRefPubMed

326.

American Diabetes Association. Overcoming therapeutic inertia. Available from https://professional.diabetes.org/meeting/other/overcoming-therapeutic-inertia. Accessed 3 Sep 2019

327.

Madenidou AV, Paschos P, Karagiannis T et al (2018) Comparative benefits and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med 169(3):165–174. https://doi.org/10.7326/M18-0443CrossRefPubMed

328.

Monnier L, Colette C (2006) Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities. Diabetes Metab 32(1):7–13. https://doi.org/10.1016/s1262-3636(07)70241-0

329.

Nicolucci A, Ceriello A, Di Bartolo P, Corcos A, Orsini Federici M (2020) Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes. Diabetes Ther 11(3):573–584. https://doi.org/10.1007/s13300-019-00732-w

330.

Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G (2016) Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes. J Diabetes 8(5):720–728. https://doi.org/10.1111/1753-0407.12355CrossRefPubMed

331.

Gabler M, Picker N, Geier S et al (2021) Real-world clinical outcomes and costs in type 2 diabetes mellitus patients after initiation of insulin therapy: a German claims data analysis. Diabetes Res Clin Pract 174:108734. https://doi.org/10.1016/j.diabres.2021.108734CrossRefPubMed

332.

McCarty D, Olenik A, McCarty BP (2019) Efficacy and safety of basal insulin/GLP-1 receptor agonist used in combination for type 2 diabetes management. J Pharm Pract 32(6):671–678. https://doi.org/10.1177/0897190018764984CrossRefPubMed

333.

Hangaard S, Laursen SH, Andersen JD et al (2021) The effectiveness of telemedicine solutions for the management of type 2 diabetes: a systematic review, meta-analysis, and meta-regression. J Diabetes Sci Technol https://doi.org/10.1177/19322968211064633

334.

Eberle C, Stichling S (2021) Effect of telemetric interventions on glycated hemoglobin A1c and management of type 2 diabetes mellitus: systematic meta-review. J Med Internet Res 23(2):e23252. https://doi.org/10.2196/23252CrossRefPubMedPubMedCentral

335.

Dicembrini I, Mannucci E, Monami M, Pala L (2019) Impact of technology on glycaemic control in type 2 diabetes: a meta-analysis of randomized trials on continuous glucose monitoring and continuous subcutaneous insulin infusion. Diabetes Obes Metab 21(12):2619–2625. https://doi.org/10.1111/dom.13845CrossRefPubMed

336.

Evans M, Welsh Z, Ells S, Seibold A (2020) The impact of flash glucose monitoring on glycaemic control as measured by HbA1c: a meta-analysis of clinical trials and real-world observational studies. Diabetes Ther Res Treat Educ Diabetes Relat Disord 11(1):83–95. https://doi.org/10.1007/s13300-019-00720-0CrossRef

337.

Martens T, Beck RW, Bailey R et al (2021) Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA 325(22):2262–2272. https://doi.org/10.1001/jama.2021.7444CrossRefPubMed

338.

Effective Practice and Organisation of Care (EPOC) (2015) EPOC taxonomy. Available from https://epoc.Cochrane.org/epoc-taxonomy. Accessed 29 Jul 2022

339.

Chan JCN, Lim LL, Wareham NJ et al (2021) The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet 396(10267):2019–2082. https://doi.org/10.1016/S0140-6736(20)32374-6

340.

World Health Organization (2021) Diabetes. Available from www.who.int/news-room/fact-sheets/detail/diabetes. Accessed 1 Aug 2022

341.

Sun H, Saeedi P, Karuranga S et al (2022) IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119. https://doi.org/10.1016/j.diabres.2021.109119CrossRefPubMed

342.

Falcetta P, Aragona M, Bertolotto A et al (2022) Insulin discovery: a pivotal point in medical history. Metabolism 127:154941. https://doi.org/10.1016/j.metabol.2021.154941CrossRefPubMed

343.

Beran D, Lazo-Porras M, Mba CM, Mbanya JC (2021) A global perspective on the issue of access to insulin. Diabetologia 64(5):954–962. https://doi.org/10.1007/s00125-020-05375-2CrossRefPubMedPubMedCentral

344.

Horwitz LI, Kuznetsova M, Jones SA (2019) Creating a learning health system through rapid-cycle, randomized testing. N Engl J Med 381(12):1175–1179. https://doi.org/10.1056/NEJMsb1900856CrossRefPubMed

345.

McGinnis JM, Fineberg HV, Dzau VJ (2021) Advancing the learning health system. N Engl J Med 385(1):1–5. https://doi.org/10.1056/NEJMp2103872CrossRefPubMed

346.

Sheikh A, Anderson M, Albala S et al (2021) Health information technology and digital innovation for national learning health and care systems. Lancet Digit Health 3(6):e383–e396. https://doi.org/10.1016/S2589-7500(21)00005-4CrossRefPubMed

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Abstract

Graphical abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

Update Innere Medizin

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2022

Up Front

Infections in the first year of life and development of beta cell autoimmunity and clinical type 1 diabetes in high-risk individuals: the TRIGR cohort

Nordic dietary patterns and cardiometabolic outcomes: a systematic review and meta-analysis of prospective cohort studies and randomised controlled trials

Associations of polysocial risk score, lifestyle and genetic factors with incident type 2 diabetes: a prospective cohort study

Progression likelihood score identifies substages of presymptomatic type 1 diabetes in childhood public health screening

Clinical variable-based cluster analysis identifies novel subgroups with a distinct genetic signature, lipidomic pattern and cardio-renal risks in Asian patients with recent-onset type 2 diabetes